Journal Article Summary
The article investigates the management of patients who experience rebound-associated vertebral fractures (RVFx) after stopping denosumab, a medication used to treat osteoporosis. This topic is significant because RVFx can lead to multiple fractures and severe pain, posing a high risk for further complications. Understanding how to effectively manage these patients is crucial for improving their quality of life and preventing additional fractures.
The authors conducted a systematic review of existing literature to compare the management strategies for patients with RVFx and those with typical osteoporotic vertebral fractures (VFx). They found that RVFx often requires stronger pain relief methods, such as opioids, due to the acute and sharp pain associated with these fractures. Unlike osteoporotic VFx, where bone-forming agents are recommended, patients with RVFx should start treatment with potent antiresorptive medications. The study emphasizes the need for a comprehensive approach that includes pain management, back protection, early mobilization, and exercise, while avoiding surgical options like vertebroplasty and kyphoplasty, which can worsen the condition.
However, the article notes several limitations, including a lack of robust data on the effectiveness of various treatments for RVFx and limited information on non-pharmacological interventions. Patients should be aware of the high risk of new fractures following RVFx and discuss their treatment options with healthcare professionals. It is essential for patients to have open conversations about their symptoms, treatment plans, and the importance of a multidisciplinary approach to manage their condition effectively.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Anastasilakis Athanasios D., Makras Polyzois, Paccou Julien, Bisbinas Ilias, Polyzos Stergios A., Papapoulos Socrates E.. Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab. Journal of Clinical Medicine 2023. DOI: 10.3390/jcm12185874. PMID: 37762815. PMCID: PMC10532339.
Featured Pill Pals Product
Tizanidine 2 mg Capsules --- Generic For Zanaflex --- Ascend
Tizanidine 2 mg Capsules — Generic For Zanaflex — Ascend is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
